|
GB0013810D0
(en)
*
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
|
ES2302845T3
(es)
*
|
2001-10-19 |
2008-08-01 |
Zymogenetics, Inc. |
Factor de crecimiento dimerizado y materiales y metodos para producirlo.
|
|
GB0303337D0
(en)
*
|
2003-02-13 |
2003-03-19 |
Celltech R&D Ltd |
Biological products
|
|
CA2529945A1
(en)
*
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
|
GB0315457D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
GB0315450D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
US20070269428A1
(en)
|
2003-11-21 |
2007-11-22 |
Celltech R&D Limited |
Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity
|
|
ATE517914T1
(de)
*
|
2004-03-08 |
2011-08-15 |
Zymogenetics Inc |
Dimere fusionsproteine und materialien und verfahren zu deren herstellung
|
|
ES2408704T3
(es)
|
2005-01-05 |
2013-06-21 |
Biogen Idec Ma Inc. |
Moléculas de unión a Cripto
|
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
WO2006116260A2
(en)
|
2005-04-26 |
2006-11-02 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
|
WO2007031734A1
(en)
|
2005-09-14 |
2007-03-22 |
Ucb Pharma S.A. |
Comb polymers
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
PT2125894T
(pt)
|
2007-03-22 |
2019-02-27 |
Biogen Ma Inc |
Proteínas de ligação incluindo anticorpos, derivados de anticorpos e fragmentos de anticorpos que se ligam especificamente ao cd154 e as suas utilizações
|
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
|
WO2009040562A1
(en)
|
2007-09-26 |
2009-04-02 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
|
US20120283415A1
(en)
|
2009-09-10 |
2012-11-08 |
Ucb Pharma S.A. |
Multivalent Antibodies
|
|
GB0916630D0
(en)
|
2009-09-22 |
2009-11-04 |
Secr Defence |
Antibody
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
WO2011117653A1
(en)
|
2010-03-25 |
2011-09-29 |
Ucb Pharma S.A. |
Disulfide stabilized dvd-lg molecules
|
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
|
EP2565667A1
(en)
|
2011-08-31 |
2013-03-06 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Direction of arrival estimation using watermarked audio signals and microphone arrays
|
|
US20140234903A1
(en)
|
2011-09-05 |
2014-08-21 |
Eth Zurich |
Biosynthetic gene cluster for the production of peptide/protein analogues
|
|
AU2012335496B2
(en)
|
2011-11-11 |
2017-05-11 |
Ucb Biopharma Sprl |
Albumin binding antibodies and binding fragments thereof
|
|
CN104684928A
(zh)
*
|
2012-08-02 |
2015-06-03 |
Jn生物科学有限责任公司 |
通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
|
|
TW201619188A
(zh)
|
2014-03-05 |
2016-06-01 |
優稀美生物醫藥公司 |
多聚體Ｆｃ蛋白質
|
|
CA2987146A1
(en)
|
2015-05-27 |
2016-12-01 |
Ucb Biopharma Sprl |
Method for the treatment of neurological disease
|
|
WO2017027325A1
(en)
|
2015-08-07 |
2017-02-16 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
EP3723791B1
(en)
|
2017-12-14 |
2024-02-21 |
CSL Behring Lengnau AG |
Recombinant igg fc multimers for the treatment of neuromyelitis optica
|
|
GB201804243D0
(en)
*
|
2018-03-16 |
2018-05-02 |
Liverpool School Tropical Medicine |
Hinge sequences
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
CN118994397A
(zh)
|
2019-05-21 |
2024-11-22 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
PE20220568A1
(es)
|
2019-05-21 |
2022-04-20 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas
|
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
|
AU2020327000A1
(en)
|
2019-08-08 |
2022-03-31 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
|
CN114401985A
(zh)
|
2019-09-13 |
2022-04-26 |
康诺贝林伦瑙有限公司 |
用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体
|
|
CN114786730A
(zh)
|
2019-11-05 |
2022-07-22 |
再生元制药公司 |
N-端scFv多特异性结合分子
|
|
BR112022012112A2
(pt)
|
2019-12-20 |
2022-09-06 |
Regeneron Pharma |
Agonistas de il2 e métodos de uso dos mesmos
|
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
|
MX2022014239A
(es)
|
2020-05-12 |
2023-02-09 |
Regeneron Pharma |
Nuevos agonistas de il10 y metodos para su uso.
|
|
TW202231292A
(zh)
|
2020-10-13 |
2022-08-16 |
美商健生生物科技公司 |
用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
US20250215081A1
(en)
|
2020-11-06 |
2025-07-03 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
IL308183A
(en)
|
2021-05-04 |
2024-01-01 |
Regeneron Pharma |
Multispecific FGF21 receptor agonists and their uses
|
|
TW202321282A
(zh)
|
2021-07-19 |
2023-06-01 |
美商再生元醫藥公司 |
Il12受體促效劑及其使用方法
|
|
TW202322846A
(zh)
|
2021-08-16 |
2023-06-16 |
美商再生元醫藥公司 |
新穎的il27受體促效劑及其使用方法
|
|
TW202334223A
(zh)
|
2021-11-11 |
2023-09-01 |
美商再生元醫藥公司 |
Ｃｄ２０－ｐｄ１結合分子及其使用方法
|
|
EP4522649A1
(en)
|
2022-05-11 |
2025-03-19 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
|
AU2023276766A1
(en)
|
2022-05-27 |
2024-12-05 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
WO2023235848A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
WO2024040247A1
(en)
|
2022-08-18 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
|
CN120712281A
(zh)
|
2022-12-16 |
2025-09-26 |
瑞泽恩制药公司 |
结合到aav颗粒的抗原结合分子和用途
|
|
US20240252601A1
(en)
|
2022-12-23 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
EP4649092A1
(en)
|
2023-01-13 |
2025-11-19 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
EP4649088A1
(en)
|
2023-01-13 |
2025-11-19 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
JP2026508317A
(ja)
|
2023-02-28 |
2026-03-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多価抗スパイクタンパク質結合分子およびその使用
|
|
IL322890A
(en)
|
2023-02-28 |
2025-10-01 |
Regeneron Pharma |
Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
|
|
KR20250156759A
(ko)
|
2023-02-28 |
2025-11-03 |
리제너론 파아마슈티컬스, 인크. |
다가 항스파이크 단백질 결합 분자 및 이의 용도
|
|
EP4709756A1
(en)
|
2023-05-10 |
2026-03-18 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
AU2024274130A1
(en)
|
2023-05-12 |
2026-01-08 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor antagonists and uses thereof
|
|
EP4630457A1
(en)
|
2023-08-18 |
2025-10-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
US20250179137A1
(en)
|
2023-12-05 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025245494A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
US20250376524A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
US20260055171A1
(en)
|
2024-06-11 |
2026-02-26 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|
|
WO2026025058A1
(en)
|
2024-07-25 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Aav viral particles retargeted to egfr-expressing cancer cells
|
|
WO2026039791A1
(en)
|
2024-08-16 |
2026-02-19 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il2 receptor agonists
|
|
WO2026076013A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted il2 receptor agonists and multispecific t-cell engagers
|
